Perjeta Injection (Pertuzumab)

Adult administration

Initial dose of 840 mg should be intravenously infused over 60 minutes, followed by a maintenance dose of 420 mg intravenously infused over 30-60 minutes every 3 weeks. This medication should be administered as an intravenous infusion and must not be administered as a rapid intravenous push or bolus. The first dose should be infused over 60 minutes, and if the patient tolerated the initial infusion well, subsequent doses can be given over 30-60 minutes.

This drug may affect the left ventricular function of the heart, so it is necessary to regularly monitor the left ventricular ejection fraction before and during administration. If there is a significant decline in cardiac function, treatment may be discontinued. When administering this drug for the first time and during maintenance doses, infusion-related reactions may occur, so patients should be closely monitored during the infusion period and for some time afterwards. If severe reactions occur, treatment should be discontinued immediately and appropriate measures taken. This drug can affect the immune system, potentially leading to hematological abnormalities such as febrile neutropenia, so conditions should be monitored periodically through blood tests, etc. Severe allergic reactions such as hypersensitivity or anaphylaxis may occur; therefore, patients should be closely observed during administration and be in a state where emergency treatment is possible. Women who may become pregnant should use effective contraception during and for some time after treatment, and it is safest not to use this drug during pregnancy. Though special dosage adjustments are not necessary for elderly patients or those with impaired kidney or liver function, caution is needed as adequate studies have not been conducted for patients with severe renal or liver impairment. This drug can frequently cause various side effects such as diarrhea, hair loss, nausea, fatigue, and neutropenia, so medical personnel should be consulted if symptoms occur. When administering, the diluted solution must be prepared under sterile conditions, and storage temperature and usage period should be strictly adhered to. Additionally, it should not be mixed with a dextrose solution. Dizziness and other symptoms may occur while driving or operating machinery, so caution is needed. This drug should only be administered under the supervision of qualified healthcare professionals, and any adverse reactions should be reported immediately and appropriate measures taken.

Serious side effects

Hives, severe swelling (edema), cold sweat, difficulty breathing, hypersensitivity, anaphylaxis, high fever, severe rash, skin peeling, pain in oral/ocular mucosa, dyspnea, asthma attack, respiratory abnormalities with cough and fever, jaundice (yellowing of skin or eyes), extreme lethargy throughout the body, sudden and very severe headache, thunderclap headache, seizure, confusion of consciousness, visual disturbances, paralysis, significantly reduced urine output, extreme fatigue throughout the body,

Mild side effects

• Diarrhea
• hair loss
• nausea
• fatigue
• neutropenia
• vomiting
• anemia
• leukopenia
• increased tearing
• stomatitis

This medication should be stored in a tightly sealed container to prevent air or moisture intrusion. In addition, it is important to store it at a refrigerated temperature between 2 and 8 degrees Celsius to maintain its efficacy.

Appearance

A vial injection filled with a colorless or pale brown solution

Package unit

1 vial/box [vial (14mL)]